enGene To Present Details Of Its Pivotal Phase 1/2 LEGEND Study Of EG-70 In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ At The American Urology Association 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
enGene Holdings Inc. (NASDAQ:ENGN) announced its participation in the American Urology Association 2024 Annual Meeting to present details of its Phase 1/2 LEGEND study of EG-70, a non-viral gene therapy for BCG-unresponsive non-muscle invasive bladder cancer. The presentation will highlight EG-70's design, addressing challenges of other treatments, and share promising initial efficacy and safety data. Complete response rates in the Phase 1 subgroup showed 70% and 60% at three and six months, respectively, indicating potential for durable remissions without significant quality of life impairment.
May 02, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
enGene Holdings Inc. is set to present promising data on EG-70, its gene therapy for bladder cancer, at the AUA 2024, indicating potential market impact.
The presentation of positive initial efficacy and safety data for EG-70 at a prestigious medical conference could significantly enhance investor confidence in enGene. The reported high response rates and the potential for durable remissions without impacting quality of life are likely to be viewed positively by the market, potentially leading to an increase in ENGN's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100